Ciccarese C.; Ferrara R.; Fantinel E.; Zecchetto C.; Simionato F.; Grego E.; Ortolani S.; Caccese M.; Bimbatti D.; Cingarlini S.; Brunelli M.; Andreini A.; Tortora G.; Massari F., Acquired hemophagocytic syndrome in a patient with synovial sarcoma: A case report, «FUTURE SCIENCE OA», 2015, 1, Article number: FSO29 , pp. 1 - 4 [Scientific article]
Piva F.; Santoni M.; Matrana M.R.; Satti S.; Giulietti M.; Occhipinti G.; Massari F.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Principato G.; Cascinu S.; Montironi R., BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2015, 15, pp. 1201 - 1210 [Scientific article]
Lopez-Beltran A.; Santoni M.; Massari F.; Ciccarese C.; Tortora G.; Cheng L.; Moch H.; Scarpelli M.; Reymundo C.; Montironi R., Bladder cancer: Molecular determinants of personalized therapy, «CURRENT DRUG TARGETS», 2015, 16, pp. 115 - 124 [Scientific article]
Iacovelli R.; Santini D.; Rizzo M.; Felici A.; Santoni M.; Verzoni E.; Masini C.; Massari F.; Calvani N.; Mosca A.; Procopio G., Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma, «CANADIAN UROLOGICAL ASSOCIATION JOURNAL», 2015, 9, pp. 263 - 267 [Scientific article]
Santoni M.; Conti A.; Procopio G.; Porta C.; Ibrahim T.; Barni S.; Guida F.M.; Fontana A.; Berruti A.; Berardi R.; Massari F.; Vincenzi B.; Ortega C.; Ottaviani D.; Carteni G.; Lanzetta G.; De Lisi D.; Silvestris N.; Satolli M.A.; Collova E.; Russo A.; Badalamenti G.; Fedeli S.L.; Tanca F.M.; Adamo V.; Maiello E.; Sabbatini R.; Felici A.; Cinieri S.; Montironi R.; Bracarda S.; Tonini G.; Cascinu S.; Santini D., Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis?, «JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH», 2015, 34, Article number: 0122 , pp. 1 - 9 [Scientific article]
Caffo O.; Ortega C.; Di Lorenzo G.; Sava T.; De Giorgi U.; Cavaliere C.; Macrini S.; Spizzo G.; Aieta M.; Messina C.; Tucci M.; Lodde M.; Mansueto G.; Zucali P.A.; Alesini D.; D'Angelo A.; Massari F.; Morelli F.; Procopio G.; Ratta R.; Fratino L.; Lo Re G.; Pegoraro M.C.; Zustovich F.; Vicario G.; Ruatta F.; Federico P.; La Russa F.; Burgio S.L.; Maines F.; Veccia A.; Galligioni E., Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger, «UROLOGIC ONCOLOGY», 2015, 33, pp. 265 - 271 [Scientific article]
Caffo O.; De Giorgi U.; Fratino L.; Alesini D.; Zagonel V.; Facchini G.; Gasparro D.; Ortega C.; Tucci M.; Verderame F.; Campadelli E.; Lo Re G.; Procopio G.; Sabbatini R.; Donini M.; Morelli F.; Sartori D.; Zucali P.; Carrozza F.; D'Angelo A.; Vicario G.; Massari F.; Santini D.; Sava T.; Messina C.; Fornarini G.; La Torre L.; Ricotta R.; Aieta M.; Mucciarini C.; Zustovich F.; Macrini S.; Burgio S.L.; Santarossa S.; D'Aniello C.; Basso U.; Tarasconi S.; Cortesi E.; Buttigliero C.; Ruatta F.; Veccia A.; Conteduca V.; Maines F.; Galligioni E., Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study, «EUROPEAN UROLOGY», 2015, 68, pp. 147 - 153 [Scientific article]
Massari F.; Ciccarese C.; Bimbatti D.; Fantinel E.; Modena A.; Simbolo M.; Brunelli M.; Artibani W.; Martignoni G.; Scarpa A.; Tortora G., Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: The fine balance between toxicity and efficacy, «ANTI-CANCER DRUGS», 2015, 26, pp. 469 - 473 [Scientific article]
Piva F.; Giulietti M.; Occhipinti G.; Santoni M.; Massari F.; Sotte V.; Iacovelli R.; Burattini L.; Santini D.; Montironi R.; Cascinu S.; Principato G., Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma, «ONCOTARGET», 2015, 6, pp. 32161 - 32168 [Scientific article]
Massari F.; Santoni M.; Ciccarese C.; Brunelli M.; Conti A.; Santini D.; Montironi R.; Cascinu S.; Tortora G., Emerging concepts on drug resistance in bladder cancer: Implications for future strategies, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2015, 96, pp. 81 - 90 [Scientific article]
Iacovelli R.; Massari F.; Albiges L.; Loriot Y.; Massard C.; Fizazi K.; Escudier B., Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma, «EUROPEAN UROLOGY», 2015, 68, pp. 154 - 160 [Scientific article]
Bria E.; Furlanetto J.; Carbognin L.; Brunelli M.; Caliolo C.; Nortilli R.; Massari F.; Pedron S.; Manfrin E.; Pellini F.; Bonetti F.; Sperduti I.; Pollini G.P.; Scarpa A.; Tortora G., Human epidermal growth factor receptor 2-positive breast cancer: Heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α Co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel, «CLINICAL BREAST CANCER», 2015, 15, pp. 16 - 23 [Scientific article]
Conteduca V.; Caffo O.; Fratino L.; Lo Re G.; Basso U.; D'Angelo A.; Donini M.; Verderame F.; Ratta R.; Procopio G.; Campadelli E.; Massari F.; Gasparro D.; Ermacora P.; Messina C.; Giordano M.; Alesini D.; Zagonel V.; Veccia A.; Lolli C.; Maines F.; De Giorgi U., Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients, «FUTURE ONCOLOGY», 2015, 11, pp. 2881 - 2891 [Scientific article]
Santoni M.; Massari F.; Iacovelli R.; Ciccarese C.; Verri E.; Burattini L.; Montironi R.; Nole F.; Tortora G.; Cascinu S., Inside the 2015 ASCO Genitourinary Cancers Symposium, «FUTURE ONCOLOGY», 2015, 11, pp. 1859 - 1862 [Scientific article]
Santoni M.; Massari F.; Del Re M.; Ciccarese C.; Piva F.; Principato G.; Montironi R.; Santini D.; Danesi R.; Tortora G.; Cascinu S., Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2015, 24, pp. 809 - 824 [Scientific article]
